Clinical Trial: Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.

U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07894640) titled 'Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.' on Oct. 19.

Brief Summary: Moyamoya disease is a relatively rare chronic cerebrovascular disease, and its exact cause is currently unknown. This disease is characterized by the gradual narrowing or even blockage of important blood vessels in the brain (the terminal portion of the internal carotid artery), while simultaneously forming an abnormal network of small blood vessels at the base of the brain. In cerebral angiography, these abnormal vessels appear as a cloud...